News

The prize recognizes “an American biomedical researcher who has made significant, progressive contributions to medicine”.

The transition from an egg to a developing embryo is one of life’s most remarkable transformations. Now Whitehead Institute researchers have used fruit flies to decipher how one aspect—control of the translation of messenger RNAs (mRNAs) into proteins—shifts as the egg becomes an the embryo.  This type of switch could tell scientists more about how human cells work and embryos develop.

Project will investigate the effectiveness and toxicity of four herbs widely used by breastfeeding women worldwide to promote human milk production

Rhogerry “Gerry” Deshycka, a graduating senior working in the lab of Whitehead Institute Founding Member Harvey Lodish, has received one of MIT’s two Randolph G. Wei Undergraduate Research Opportunities Program (UROP) awards for 2017 and MIT’s 2017 John L. Asinari Award. 

Cultured human cells are the foundation for disease and drug research. Now Whitehead Institute researchers have designed a growth medium that more closely resembles the cells’ environment in the body—and demonstrated that, relative to decades-old recipes that have remained the workhorses of cell culture studies, it significantly alters the cells’ inner workings.

Prize bestowed for discovery of the mTOR pathway’s impact on age-related diseases

Whitehead Institute scientists have identified a gene that could help clinicians discern which patients have aggressive forms of early stage breast cancer, which could prevent hundreds of thousands of women from undergoing unnecessary treatment and save millions of dollars.

The budget proposed on March 15, 2017 would cut National Institutes of Health funding by an estimated 20 percent.

Using red blood cells modified to carry disease-specific antigens, a team of scientists from Whitehead Institute and Boston Children’s Hospital have prevented and alleviated two autoimmune diseases—multiple sclerosis (MS) and type 1 diabetes—in early stage mouse models.  This research is an exciting step toward therapeutics for autoimmune diseases, which affect an estimated 23 million Americans.

Researchers at Whitehead Institute have now uncovered a role for the protein-folding chaperone HSP90 in humans, not only as a modifier of the effects of mutations, but as a mediator of the impact of the environment on the function of mutant proteins. And these effects of HSP90 can alter the course of human diseases.